Titan Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Titan Pharmaceuticals
TTNP Stock  USD 3.72  0.09  2.48%   
Titan Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Titan Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Titan Pharmaceuticals financial statements helps investors assess Titan Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Titan Pharmaceuticals' valuation are summarized below:
Gross Profit
-4.4 M
Market Capitalization
3.3 M
Enterprise Value Revenue
7.0433
Revenue
3 K
Earnings Share
(6.64)
There are currently one hundred twenty fundamental trend indicators for Titan Pharmaceuticals that can be evaluated and compared over time across competition. Investors and active traders are advised to double-check Titan Pharmaceuticals' current fundamental performance against the performance between 2010 and 2025 to make sure the trends are evolving in the right direction. As of 03/18/2025, Market Cap is likely to drop to about 159 K. In addition to that, Enterprise Value is likely to grow to about (695.3 K)

Titan Pharmaceuticals Total Revenue

201,020

Check Titan Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Titan Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 95.8 K, Interest Expense of 31.7 K or Total Revenue of 201 K, as well as many indicators such as Price To Sales Ratio of 36.84, Dividend Yield of 0.0015 or PTB Ratio of 0.8. Titan financial statements analysis is a perfect complement when working with Titan Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Titan Pharmaceuticals Correlation against competitors.
To learn how to invest in Titan Stock, please use our How to Invest in Titan Pharmaceuticals guide.

Titan Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets6.9 M7.3 M11.6 M
Slightly volatile
Short and Long Term Debt Total483.1 K508.5 K4.7 M
Slightly volatile
Other Current Liabilities443.7 K467.1 K1 M
Very volatile
Total Current Liabilities1.6 M1.7 M5.4 M
Slightly volatile
Property Plant And Equipment Net74.3 K78.2 K744 K
Slightly volatile
Accounts Payable380.2 K400.2 K2.1 M
Slightly volatile
Cash8.3 M6.1 M8.2 M
Slightly volatile
Non Current Assets Total58.1 K61.2 K929.2 K
Slightly volatile
Cash And Short Term Investments5.8 M6.1 M8 M
Slightly volatile
Net Receivables1.6 M1.2 M2 M
Slightly volatile
Common Stock Shares Outstanding908 K864.8 K295.3 K
Slightly volatile
Liabilities And Stockholders Equity6.9 M7.3 M11.6 M
Slightly volatile
Other Stockholder Equity481.2 M458.2 M211 M
Slightly volatile
Total Liabilities1.6 M1.7 M10.2 M
Slightly volatile
Total Current Assets6.9 M7.2 M10.7 M
Slightly volatile
Short Term Debt483.1 K508.5 K1.8 M
Slightly volatile
Other Current Assets170.1 K179.1 K1.3 M
Slightly volatile
Property Plant And Equipment Gross883.3 K890.1 K1.1 M
Pretty Stable
Common Stock Total Equity6 K6.3 K130.5 M
Slightly volatile
Property Plant Equipment826.4 K824.5 K884.7 K
Pretty Stable
Current Deferred Revenue10.3 K10.8 K2.5 M
Slightly volatile
Other Liabilities273.6 K288 K3.4 M
Slightly volatile
Net Tangible Assets4.7 M4.6 M5.6 M
Slightly volatile
Capital Surpluse447.7 M426.4 M201.9 M
Slightly volatile
Non Current Liabilities Other1 M557.1 K1 M
Slightly volatile
Long Term Debt Total4.2 M4.6 M3.8 M
Slightly volatile
Net Invested Capital4.8 M6.4 M6.6 M
Slightly volatile
Short and Long Term Debt870.8 K450 K1.8 M
Slightly volatile
Net Working Capital3.8 M5.9 M4.4 M
Pretty Stable
Capital Stock1.7 K1.8 K13.2 K
Pretty Stable
Capital Lease Obligations55.6 K58.5 K314.7 K
Slightly volatile

Titan Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Revenue201 K211.6 K3.7 M
Slightly volatile
Other Operating Expenses13 M6.7 M11.7 M
Pretty Stable
Total Operating Expenses13 M6.6 M11.5 M
Pretty Stable
Selling General Administrative5.4 M6.4 M5 M
Slightly volatile
Research Development1.6 M1.7 M6 M
Slightly volatile
Interest Income4.3 K4.5 K1.8 M
Slightly volatile
Reconciled Depreciation217.6 K138.6 K323.7 K
Slightly volatile
Selling And Marketing Expenses95.8 K100.8 K4.1 M
Slightly volatile

Titan Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow2.7 M2.8 M7.5 M
Slightly volatile
Depreciation95.8 K100.8 K225.2 K
Pretty Stable
End Period Cash Flow8.8 M6.1 M8.3 M
Pretty Stable
Stock Based Compensation1.1 M1.2 M1.1 M
Pretty Stable
Issuance Of Capital Stock7.2 M8.2 M9.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio36.8438.78917
Slightly volatile
Dividend Yield0.00150.00170.0019
Slightly volatile
Days Sales Outstanding2 K1.9 K547
Slightly volatile
Stock Based Compensation To Revenue7.946.332.9598
Slightly volatile
Capex To Depreciation0.01530.01615.2681
Slightly volatile
Inventory Turnover0.911.660.8446
Slightly volatile
Days Of Inventory On Hand189178222
Slightly volatile
Sales General And Administrative To Revenue52.4534.6715.9529
Slightly volatile
Average Inventory0.40.450.4906
Slightly volatile
Research And Ddevelopement To Revenue11.3611.9612.1338
Pretty Stable
Capex To Revenue0.01190.01250.0925
Very volatile
Cash Per Share9.8210.34328
Very volatile
Current Ratio8.346.392.9986
Slightly volatile
Receivables Turnover0.190.25.6355
Slightly volatile
Capex Per Share0.00230.002416.1892
Very volatile
Revenue Per Share0.210.22212
Very volatile
Interest Debt Per Share0.640.68380
Very volatile
Debt To Assets0.07630.08040.5029
Slightly volatile
Graham Number650390420
Slightly volatile
Operating Cycle2 K1.9 K680
Slightly volatile
Quick Ratio8.316.392.9424
Slightly volatile
Net Income Per E B T0.90.99721.0943
Very volatile
Cash Ratio3.955.382.1522
Slightly volatile
Days Of Inventory Outstanding189178222
Slightly volatile
Days Of Sales Outstanding2 K1.9 K663
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.091.150.9871
Slightly volatile
Fixed Asset Turnover2.963.114.9007
Slightly volatile
Debt Ratio0.07630.08040.5029
Slightly volatile
Price Sales Ratio36.8438.78917
Slightly volatile
Asset Turnover0.01950.02050.2545
Slightly volatile

Titan Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap159 K167.4 K353.8 M
Slightly volatile

Titan Fundamental Market Drivers

Cash And Short Term Investments6.8 M

Titan Upcoming Events

13th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Titan Pharmaceuticals Financial Statements

Titan Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Titan Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Titan Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Titan Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue10.8 K10.3 K
Total Revenue211.6 K201 K
Cost Of Revenue100.8 K95.8 K
Stock Based Compensation To Revenue 6.33  7.94 
Sales General And Administrative To Revenue 34.67  52.45 
Research And Ddevelopement To Revenue 11.96  11.36 
Capex To Revenue 0.01  0.01 
Revenue Per Share 0.22  0.21 
Ebit Per Revenue(35.59)(37.37)

Additional Tools for Titan Stock Analysis

When running Titan Pharmaceuticals' price analysis, check to measure Titan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Titan Pharmaceuticals is operating at the current time. Most of Titan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Titan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Titan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Titan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY